Core Insights - The company is entering a pivotal year marked by significant progress in patient access, clinical development, and operational readiness [1] - The discussion will include forward-looking statements that are subject to risks and uncertainties [2] Company Developments - Recent collaboration with Zydus has been closed, which is expected to enhance operational capabilities for the company [3] - There is an expansion of France's reimbursed AAC program, particularly relevant for sarcomas, indicating a growing interest from physicians and patients [3] Leadership Engagement - The leadership team, including the Chief Medical Officer, Chief Medical Affairs Officer, and Chief Commercial Officer, will participate in a live Q&A session to address stakeholder inquiries [4]

每经AI快讯，有投资者在投资者互动平台提问：贝达药业投资翰思艾泰，成为其重要股东之一。请问 翰思艾泰创新方向和成果有哪些？贝达药业是否有在相关技术和销售方面进行合作？ 贝达药业（300558.SZ）1月21日在投资者互动平台表示，翰思艾泰生物医药科技（武汉）股份有限公司 是一家专注于结构生物学、转化医学及临床开发的创新型生物科技公司，已建立聚焦肿瘤及免疫疾病的 自主创新药物产品管线，并搭建了拥有全球专利的高亲和力、长半衰期抗体筛选平台，以及肿瘤靶向 Geographical Positioning Small molecule-Antibody（GPSmAb）创新技术平台，详细内容您可以查阅翰思 艾泰官网。公司目前持有翰思艾泰4.72%股份，如有其他重大合作将按法律法规的规定及时披露。 （记者 王晓波） ...